Courtesy of Benzinga.
CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has entered into a definitive agreement to acquire On-X Life Technologies Holdings, Inc. (“On-X”), an Austin, Texas-based, privately held mechanical heart valve company.
J. Patrick Mackin, Chairman, President, and Chief Executive Officer of CryoLife, said, “We believe this will be a transformative acquisition for CryoLife that will significantly enhance the size of our addressable market and growth potential. This transaction will provide CryoLife access to the $220 million mechanical valve market with a highly advanced portfolio of products. On-X valves have been implanted in over 200,000 patients, and On-X has achieved a 13% revenue CAGR over the past four years with modest sales and marketing support. We are very excited about the outlook for continued growth for several reasons. First, the On-X aortic valve is the only mechanical valve to receive FDA labeling requiring an INR (international normalized ratio) level of only 1.5-2.0. This labeling provides the On-X valve with a distinct competitive advantage. Second, with the addition of the On-X sales team to the CryoLife team, our U.S. cardiac surgery sales force will more than double. Third, as the power of On-X’s technology and its supporting robust clinical data become more widely known through our expanded sales organization, we believe the acquired portfolio will continue to post double-digit compounded growth from 2016-2020. Finally, we believe we will also see strong synergy between our product portfolios, which will drive cross-selling opportunities across our entire business.”
Clyde Baker, President and Chief Executive Officer of On-X, commented, “On-X is extremely excited to join forces with CryoLife and we believe CryoLife is well suited to take the On-X business to the next level. We expect this transaction to enhance the growth trajectory of On-X products through the additional resources provided by a larger, global cardiac surgery company.”
On-X generated revenue of approximately $33 million in 2014, representing compound annual growth of approximately 13% over the preceding four years.
Strategic Rationale for the Transaction
Entry into new addressable market opportunity of approximately $220 million annually
Enhanced revenue growth profile and cross-selling opportunities
Diversification of business mix, margin expansion, and reduced reliance on the tissue business
Acquired products that are highly advanced, clearly differentiated, and backed by compelling clinical data
Relatively low penetration rates of On-X valves, providing potential for multi-year growth
Enhancement and leverage of global sales and distribution network
Acceleration of the transition to direct sales in select international markets
Strengthened strategic focus on aortic and mitral valve repair and replacement surgery
Mechanical heart valve business is complementary to CryoLife’s existing tissue valve business
Terms of the Agreement
Under the terms of the agreement, CryoLife will acquire On-X for an upfront payment of $130 million on a cash-free, debt-free basis (subject to certain adjustments), consisting of approximately 70% in cash and 30% in CryoLife common stock. CryoLife expects to finance the cash portion of the transaction primarily with proceeds from the issuance of a new credit facility and available cash. CryoLife has received a commitment from Capital One, Fifth Third Bank, and Citizens Bank for a 5-year, $95 million senior secured facility, which includes a $75 million term loan and a $20 million revolving credit facility.
The merger agreement has been approved by both companies’ boards of directors and On-X’s stockholders, and the transaction is expected to close in January 2016, subject to the satisfaction of customary closing conditions.
Financial Guidance
CryoLife will issue its initial 2016 financial guidance during its year-end earnings conference call, currently scheduled during the third week of February 2016.
During the evaluation of this transaction, CryoLife’s board of directors undertook a review of the Company’s current dividend practices and, consistent with the practices of other similarly sized public companies, determined that it would be in the best interest of shareholders to discontinue dividend payments for the foreseeable future.
Posted-In: News M&A Press Releases
